Positives

• An 18-year-old with MCAS having two to three flares per week saw hospital admissions drop and quality of life markedly improve after starting continuous diphenhydramine and imatinib PMC.
  
  
• A patient with three decades of MCAS attacks unresponsive to oral mast cell drugs experienced dramatic improvement on low-dose imatinib, with episode intervals stretching from weekly to once every two to three months PMC.
  
  

Negatives

• In a refractory MCAS cohort of 23 patients on imatinib, only 11 had clinical improvement, meaning roughly half of patients did not benefit ScienceDirect.
  
  
• Patients commonly experienced fluid retention, nausea, vomiting, and muscle cramps on imatinib, with some reporting persistent foot cramping Rare Disease Advisor.
  
  

Hurdles & Side Effects

• Imatinib is FDA-labeled only for KIT-D816V-negative aggressive systemic mastocytosis, so MCAS use is off-label and many insurers refuse coverage without prior authorization PMC.
  
  
• Patients have to titrate slowly from 100 mg up to 400 mg daily under specialist supervision because mast cell physicians are still few and the dosing protocol for MCAS is non-standardized PMC.